Curcumin prophylaxis mitigates the incidence of hypobaric hypoxia-induced altered ion channels expression and impaired tight junction proteins integrity in rat brain

Journal of Neuroinflammation

V Vijayalakshmi¹  S Saumya¹  P Himadri¹  M Titto¹  SKS Sarada¹ 

[1] Haematology Division, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur 110054, Delhi, India

关键词: Inflammation;    Tight junction proteins;    ENaC;    Na+/K+-ATPase;    Fluid reabsorption;    HIF-1α;    NF-κB;    Cerebral edema;    Hypoxia;    Curcumin;   

Others  :  1221963
DOI  :  10.1186/s12974-015-0326-4

 received in 2014-12-21, accepted in 2015-05-20,  发布年份 2015

【 摘 要 】

Background

The present study was proposed to elucidate the prophylactic role of curcumin in the prevention of hypoxia-induced cerebral edema (HACE).

Methods

Rats were exposed to simulated hypobaric hypoxia at 7620 m for 24 h at 25 ± 1 °C. Transvascular leakage, expression of transcriptional factors (nuclear factor-kappa B (NF-κB) and hypoxia inducible factor 1 alpha (Hif-1α) and also the genes regulated by these transcriptional factors, sodium potassium-adenosine triphosphatase (Na⁺/K⁺-ATPase) and endothelial sodium channel (ENaC) levels and brain tight junction (TJ) proteins like ZO-1, junctional adhesion molecule C (JAMC), claudin 4 and claudin 5 levels were determined in the brain of rats under hypoxia by Western blotting, electro mobility shift assay, ELISA, immunohistochemistry, and histopathology along with haematological parameters. Simultaneously, to rule out the fact that inflammation causes impaired Na⁺/K⁺-ATPase and ENaC functions and disturbing the TJ integrity leading to cerebral edema, the rats were pre-treated with curcumin (100 mg/kg body weight) 1 h prior to 24-h hypoxia.

Results

Curcumin administration to rats, under hypoxia showed a significant decrease (p < 0.001) in brain water content (3.53 ± 0.58 wet-to-dry-weight (W/D) ratio) and transvascular leakage (136.2 ± 13.24 relative fluorescence units per gram (r.f.u./g)) in the brain of rats compared to control (24-h hypoxia) (7.1 ± 1.0 W/D ratio and 262.42 ± 24.67 r.f.u./g, respectively). Curcumin prophylaxis significantly attenuated the upregulation of NF-κB (p < 0.001), thereby leading to concomitant downregulation of pro-inflammatory cytokine levels (↓IL-1, IL-2, IL-18 and TNF-α), cell adhesion molecules (↓P-selectin and E-selectin) and increased anti-inflammatory cytokine (↑IL-10). Curcumin stabilized the brain HIF-1α levels followed by maintaining VEGF levels along with upregulated Na⁺/K⁺-ATPase and ENaC levels (p < 0.001) under hypoxia. Curcumin restored the brain ZO-1, JAMC, claudin 4 and claudin 5 levels (p < 0.001) under hypoxia. Histopathological observations revealed the absence of edema and inflammation in the brain of rats supplemented with curcumin.

Conclusions

These results indicate that curcumin is a potent drug in amelioration of HACE as it effectively attenuated inflammation as well as fluid influx by maintaining the tight junction proteins integrity with increased ion channels expression in the brain of rats under hypoxia.

【 授权许可】

   
2015 Sarada et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Figure 5.

Fig. 8.

Fig. 9.

Fig. 10.

【 参考文献 】

• [1]Hackett PH, Roach RC: High altitude cerebral edema. High Alt Med Biol 2004, 5:136-46.
• [2]Wilson M, Newman SM, Imray C: The cerebral effects of ascent to high altitude. Lancet Neurol 2009, 8(2):175-91.
• [3]Dickinson J: Severe acute mountain sickness. Postgrad Med J 1979, 55:454-8.
• [4]Clarke C: High altitude cerebral oedema. Int J Sports Med 1988, 9:170-4.
• [5]Basnyat B, Subedi D, Sleggs J, Lemaster J, Bhasyal G, Aryal B, et al.: Disoriented and ataxic pilgrims: an epidemiological study of acute mountain sickness and high altitude cerebral edema at a sacred lake at 4300 m in the Nepal-Himalayas. Wilderness-Environ-Med 2000, 11:89-93.
• [6]Schoch HJ, Fischer S, Marti HH: Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002, 125:2549-57.
• [7]Kallenberg K, Dehnert C, Dörfler A, Schellinger PD, Bailey DM, Knauth M, et al.: Microhemorrhages in nonfatal high-altitude cerebral edema. J Cereb Blood Flow Metab 2008, 28:1635-42.
• [8]Stelzner TJ, O’Brien RF, Sato K, Wail JV: Hypoxia induced increase in pulmonary transvascular protein escape in rats: modulation by glucocorticoids. J Clin Intvention 1988, 82:1840-7.
• [9]Mark SK, Davis TP: Cerebral micro vascular changes in permeability and tight junctions induced by hypoxia reoxygenation. Am J Physiol Heart Circ Physiol 2002, 282:H1485-94.
• [10]Tsukamoto T, Nigam SK: Role of tyrosine phosphorylation in the reassembly of occluding and other tight junction proteins. Am J Physiol Renal Physiol 1999, 276(5):F737-50.
• [11]Tsukita S, Furuse M: Occludin and claudins in tight junction strands: leading or supporting players? Trends Cell Biol 1999, 9:268-73.
• [12]Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S: Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of Cludins. J Cell Biol 1999, 147:1351-63.
• [13]Kristian T, Siesjo BK: Calcium in ischemic cell death. Stroke 1998, 29:705-18.
• [14]Madjdpour C, Jewell UR, Kneller S, Ziegler U, Schwendener R, Booy C, et al.: Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol 2003, 284:L360-7.
• [15]Himadri P, Sarada SK, Chitharanjan M, Dhananjay S: Role of oxidative stress and inflammation in hypoxia-induced cerebral edema: a molecular approach. High Alt Med Biol 2010, 11:231-44.
• [16]Grissom CK, Roach RC, Sarnquist FH, Hackett PH: Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992, 116:461-5.
• [17]Milledge JS, West JB, Schoene RB: High altitude cerebral edema. In High altitude medicine and physiology. 3rd edition. Hodder Arnold, London; 2000:248.
• [18]Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggrawal BB: Curcumin and cancer: an old disease with an age old solution. Cancer Lett 2008, 267:133-64.
• [19]Piper JT, Singhal SS, Salameh M, Torman RT, Awasthi YC, Awasthi S: Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 1998, 30:445-56.
• [20]Thapliyal R, Maru GB: Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 2001, 39:541-7.
• [21]Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R: Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995, 94:79-83.
• [22]Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, et al.: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappa B activation via the NIK/IKK signalling complex. Oncogene 1999, 18:6013-20.
• [23]Brennan P, O’Neill LA: Inhibition of nuclear factor kappaB by direct modification in whole cells—mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem Pharmacol 1998, 55:965-73.
• [24]Benjamin H, Theis MK, Jane KM, Roach R, Yip HC, Moore LG: Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med 1993, 118:587-92.
• [25]Kohli K, Ali J, Ansari MJ, Raheman Z: Curcumin: a natural anti-inflammatory agent. Indian J Pharmacol 2004, 37(3):141-7.
• [26]Majeed M, Badmaev V, Shivakumar U, Rajendran R: Curcuminoids-antioxidant phytonutrients. Nutriscience Publishers Inc., Piscataway, NJ; 1995.
• [27]Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, et al.: Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmaco 1999, 58:1167-72.
• [28]Barik A, Priyadarsini KI, Mohan H: Photophysical studies on binding of curcumin to bovine serum albumins. Photochem Photobiol 2003, 77:597-603.
• [29]Ravindranath V, Chandrasekhara N: Absorption and tissue distribution of curcumin in rats. Toxicology 1980, 16:259-65.
• [30]Sahdeo P, Amit KT, Bharat BA: Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014, 46(1):2-18.
• [31]Basu M, Sawney RC, Kumar S, Pal K, Prasad R, Selwamurthy W: Glucocorticoids as prophylaxis against acute mountain sickness. Clin Endocrinol 2002, 57:761-7.
• [32]Baba M, Oshi R, Saeki K: Enhancement of blood-brain barrier permeability to sodium fluorescence by stimulation of mu opiod receptors in mice. Naunyn Schmiedeberges Arch Pharmacol 1998, 337:423-8.
• [33]Hu X, Taylor ON, Qiu J, Rea HC, Fabian R, Rassin DK, et al.: Activation of nuclear factor-kB signaling pathway by interleukin-1 after hypoxia/ischemia in neonatal rat hippocampus and cortex. J Neurochem 2005, 93:26-37.
• [34]Beytut E, Soznen M, Erginosoy E: Immunohistochemical detection of pulmonary surfactant protein and retro viral antigen in lungs of sheep with pulmonary adenomatoris. J Comparative Pathol 2009, 140:45-53.
• [35]Ward MP, Milledge JS, West JB: High altitude medicine and physiology. 2nd edition. Chapman & Hall Medical, London; 1995.
• [36]Saunders PU, Pyne DB, Gore CJ: Endurance training at altitude. High Altitude Med Biol 2009, 10:135-48.
• [37]Fudge BW, Pringle JSM, Maxwell NS, Turner G, Ingham SA, Jones AM: Altitude training for elite endurance performance: a 2012 update. Curr Sports Med Reports 2012, 11(3):148-54.
• [38]Garvican L, Martin D, Quod M, Stephens B, Sassi A, Gore C: Time course of the hemoglobin mass response to natural altitude training in elite endurance cyclists. Scand J Med Sci Sports 2012, 22(1):95-103.
• [39]Pottgiesser T, Garvican LA, Martin DT, Featonby JM, Gore CJ, Schumacher YO: Short term haematological effects upon completion of a four week simulated altitude camp. Int J Sports Physiol Perf 2012, 7:79-83.
• [40]Van Den P, Kenneth NSM, Rocha S: Regulation of hypoxia-inducible factor 1-alpha by NF-kappaB. Biochem J 2008, 15:477-84.
• [41]Stanimirovic D, Satoh K: Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol 2000, 10:113-26.
• [42]Holger KE, Peter C: Hypoxia and Inflammation. N Engl J Med 2011, 364:656-65.
• [43]Arbiser JL, Klauber N, Rohan R, Van Leewen R, Huangmt MT, Fisher C, et al.: Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998, 4:376-83.
• [44]Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, Thompson HW, et al.: Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 2003, 44:4163-70.
• [45]Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al.: NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 2008, 5:807-11.
• [46]Xiong M, Elson G, Legasda D, Leibovich SM: Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol 1998, 153:587-98.
• [47]Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E: VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaB alpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003, 116:665-74.
• [48]Robert W, Sean BJ, Bryan A, Laffitte AC, Lining P, Peter T: Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptor. J Biol Chem 2004, 279(11):9905-11.
• [49]Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999, 237:97-132.
• [50]Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H: Inhibition of NFKB activity decreases the VEGF mRNA expression in MDA-MB-231. Breast Cancer Cells Treat 2002, 73:237-43.
• [51]Witt KA, Mark KS, Hom S, Davis TP: Effects of hypoxia reoxygenation on rat blood brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2003, 285:H2820-31.
• [52]Garcia-Alloza M, Bottelli LA, Rozkalhe A, Hyman BT, Bacskai BJ: Curcumin labels amyloid pathology in vivo, disrupts existing plaques and partially restores distorted nutrients in an Alzheimer mouse model. J Neurochem 2007, 102:1095-104.
• [53]Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT: Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem 2006, 49:6111-9.
• [54]Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-900.
• [55]Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al.: Phase I clinical trial of oral curcumin biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 15:200410-6847.
• [56]Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, et al.: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006, 4:1035-8.
• [57]Durgaprasad S, Pai CG, Vasanth K, Alvres JF, Namitha S: A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005, 122(4):315-8.
• [58]Holt PR, Katz S, Kirshoff R: Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005, 50:2191-3.
• [59]Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al.: Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:1502-6.
• [60]Rasyid A, Rahman AR, Jaalam K, Lelo A: Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr 2002, 11(4):314-8.
• [61]Heng MC, Song MK, Harker J, Heng MK, et al.: Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 2000, 143:937-49.
• [62]Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, et al.: A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter 2007, 12:238-43.
• [63]Yang GY, Chen SF, Kinouchi H, Chan PH, Weinstein PR: Edema, cation content, and ATPase activity after middle cerebral artery occlusion in rats. Stroke 1992, 23:1331-6.
• [64]Siesjö BK: Pathophysiology and treatment of focal cerebral ischemia: Part II: mechanisms of damage and treatment. J Neurosurg 1992, 77(3):337-54.
• [65]Behl C, Moosmann B: Oxidative nerve cell death in Alzheimer’s disease and stroke: antioxidants as neuroprotective compounds. Biol Chem 2002, 383:521-36.
• [66]Hennings H, Yuspa SH, Holbrook KA: Inhibition of calcium-induced terminal differentiation of epidermal cells by ouabain and A23187. Curr Probl Dermatol 1983, 11:109-25.
• [67]Heerlein K, Schulze A, Holtz L, Bartsch P, Mairbaurl H: Hypoxia decreases cellular ATP demand and inhibits mitochondrial respiration of A549 cells. Am J Respi Cell Mol Biol 2005, 32:44-51.
• [68]Fischer S, Wobben M, Kleinstuck J, Renz D, Schaper W: Effect of astroglial cells on hypoxia-induced permeability in PBMEC cells. Am J Physiol Cell Physiol 2000, 279:C935-44.
• [69]Sharkey AM, Day K, Mc P, Malik S, Licence D, Smith SK, et al.: Vascular endothelial growth factor expression in human endometrium and regulated by hypoxia. J Clin Endocrinal Metab 2000, 85:402-9.
• [70]Zoppo GD, Ginis I, Hallenbeck JM, Indecola C, Wang X, Feuerstein GZ: Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000, 10:95-112.
• [71]Qiquan Z, Xiaoling T, Jing W, Bo Z, Ping G: Increased permeability of blood–brain barrier caused by inflammatory mediators is involved in high altitude cerebral edema. Sci Res Essays 2011, 6(3):607-15.
• [72]Firouzi Z, Lari P, Rashedinia M, Ramezani M, Iranshahi M, Abnous K: Proteomics screening of molecular targets of curcumin in mouse brain. Life Sci 2014, 98(1):12-7.
• [73]Hackett PH: The cerebral etiology of high altitude cerebral edema and acute mountain sickness. Wilderness Environ Med 1999, 10(2):97-109.
• [74]Cymerman A, Rock PB: Medical problems in high mountain environments: a handbook for medical officers. US ARIEM Techn Note 1994, 94–2:1-49.
• [75]Ling NH, Perry PJ, Tsuang MT: Side effects of corticosteroid therapy. Arch Gen Psychiatry 1981, 38:471-7.